BiotechTube

Alectinib + Crizotinib

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

Conditions

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

Trial Timeline

Aug 3, 2016 → Jun 30, 2026

NCT ID
NCT02838420

About Alectinib + Crizotinib

Alectinib + Crizotinib is a phase 3 stage product being developed by Roche for Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02838420. Target conditions include Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT03194893Phase 3Active
NCT02838420Phase 3Active
NCT02075840Phase 3Completed

Competing Products

20 competing products in Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

See all competitors
ProductCompanyStageHype Score
CS-7017 + PaclitaxelDaiichi SankyoPhase 1/2
24
efatutazone + paclitaxelDaiichi SankyoPhase 2
35
Lenvatinib 24 mgEisaiPhase 2
27
Lenvatinib + NivolumabOno PharmaceuticalPhase 2
39
durvalumab + tremelimumabAstraZenecaPhase 1
29
PembrolizumabMerckPhase 2
35
LDK378 + AUY922NovartisPhase 1
29
ceritinibNovartisPre-clinical
30
LDK378NovartisPhase 1
29
CeritinibNovartisPhase 2
27
Gemcitabine + ribociclib + sonidegib + trametinib + filgrastimNovartisPhase 1
29
dabrafenib/trametinibNovartisPhase 2
42
Trametinib + PaclitaxelNovartisPhase 1
33
Sunitinib MalatePfizerPhase 2
35
Crizotinib (PF-02341066)PfizerPhase 2
35
LorlatinibPfizerPhase 2
31
CrizotinibPfizerPhase 1/2
32
Cemiplimab + XL092Regeneron PharmaceuticalsPhase 1
36
Etirinotecan pegolNektar TherapeuticsPhase 2
29
BevacizumabNovocurePhase 2
36